Phase I VTX-2337 (TLR8 Agonist ) trial at Mayo in Arizona
Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer http://clinicaltrials.gov/ct2/html/i...e/triangle.gif Purpose This is a multi-center, Phase I study of a new investigational drug, VTX-2337, that may stimulate the immune system to help fight cancer. The purpose of the study is to assess the safety of the investigational drug and to identify the highest dose that is well-tolerated. The pharmacology of VTX-2337 will also be evaluated.This study is currently recruiting participants. Verified by VentiRx Pharmaceuticals Inc., November 2008 Sponsored by: VentiRx Pharmaceuticals Inc. Information provided by: VentiRx Pharmaceuticals Inc. ClinicalTrials.gov Identifier: NCT00688415 MedlinePlus related topics: Cancer Lymphoma U.S. FDA Resources Study Type: Interventional Study Design: Non-Randomized, Open Label, Single Group Assignment Official Title: A Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacology of VTX-2337 When Administered to Adult Subjects With Advanced Solid Tumors or Lymphoma Further study details as provided by VentiRx Pharmaceuticals Inc.: Primary Outcome Measures:
Secondary Outcome Measures:
Estimated Enrollment: 21 Study Start Date: November 2008 Estimated Primary Completion Date: June 2009 (Final data collection date for primary outcome measure) Intervention Details:
http://clinicaltrials.gov/ct2/html/i...e/triangle.gif Eligibility Ages Eligible for Study: 18 Years and older Genders Eligible for Study: Both Accepts Healthy Volunteers: No Criteria Other specific eligibility criteria may apply. Examination by the investigator is necessary to fully determine eligibility. Inclusion Criteria:
http://clinicaltrials.gov/ct2/html/i...e/triangle.gif Contacts and Locations Please refer to this study by its ClinicalTrials.gov identifier: NCT00688415 Contacts Contact: Amber Mann, BS, MBA (910) 558-2956 Locations United States, Arizona Mayo Clinic Recruiting Scottsdale, Arizona, United States Contact: Deborah Gallagher, RN 480-301-4038 Gallagher.Deborah@mayo.edu Principal Investigator: Dr. Northfelt, M.D. Scottsdale Healthcare Recruiting Scottsdale, Arizona, United States Contact: Joyce Ingold, Rn, MSN, OCN 480-323-1339 jingold@shc.org Principal Investigator: Dr. Ramanathan, MD Sponsors and Collaborators VentiRx Pharmaceuticals Inc. http://clinicaltrials.gov/ct2/html/i...e/triangle.gif More Information Responsible Party: VentiRx Pharmaceuticals ( Kristi Manjarrez/Sr Director of Clinical Affairs ) Study ID Numbers: VRXP-A101 First Received: May 29, 2008 Last Updated: November 10, 2008 ClinicalTrials.gov Identifier: NCT00688415 [history] Health Authority: United States: Food and Drug Administration Study placed in the following topic categories: Lymphatic Diseases Immunoproliferative Disorders Lymphoproliferative Disorders Lymphoma Additional relevant MeSH terms: Neoplasms Neoplasms by Histologic Type Immune System Diseases ClinicalTrials.gov processed this record on December 19, 2008 |
VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
(posted on 04/12/2008) First Selective TLR8 Agonist to Advance to Clinical Trials SAN DIEGO, Dec. 4 - VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) agonists for the treatment of cancer, respiratory and autoimmune diseases, announced today that it has initiated a Phase I clinical trial of VTX-2337, a selective TLR8 agonist for the treatment of cancer. The multi-center clinical trial is being conducted at the Mayo Clinic Arizona and TGen Drug Development Services (TD2) both in Scottsdale, Arizona. “We are delighted to advance the first molecule from our Toll-Like Receptor 8 platform, VTX-2337, into the clinic,” said Michael Kamdar, Executive Vice President and Chief Business Officer at VentiRx. “This represents a significant milestone for VentiRx and our TLR efforts as we have rapidly advanced into a clinical development company with a novel molecule that may have broad application in the treatment of cancer.” VTX-2337 is a small molecule TLR8 agonist that is expected to be used in combination with standard of care for the treatment of patients with cancer. Preclinical evaluation of VTX-2337 suggests that it may play a key role in augmenting the innate arm of the immune system and provide a valuable addition to various treatment regimens in oncology. The first clinical trial will investigate the safety and pharmacology of multiple doses of VTX-2337 in patients with late stage cancer. “VTX-2337 is the first selective TLR8 compound to reach the clinic and we are hopeful that modulation of the innate immune response will provide a benefit to patients in a number of oncology indications,” said Dr. Robert Hershberg, Executive Vice President and Chief Medical Officer at VentiRx. About VentiRx Pharmaceuticals VentiRx Pharmaceuticals, Inc. is a biopharmaceutical company committed to the development and commercialization of novel medicines for the treatment of cancer, respiratory and autoimmune diseases. The Company's initial focus is on developing small molecule TLR-based product candidates for oncology and allergy. VentiRx is a privately held organization headquartered in San Diego with operations in Seattle. For additional information, please visit www.ventirx.com. |
Phase I VTX 2337 TLR8 Agonist trial at Mayo in Arizona
I would find it helpful if users had an area to post clinical trials they come across. For instance, I just found a trial of Gemzar and Alimta at the Mayo clinic for gallbladder cancer.
|
All times are GMT -7. The time now is 09:14 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021